Bolt Biotherapeutics Inc (BOLT)

May 01, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia

May 01, 2025

Apr 30, 2025

Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus

Apr 30, 2025

Apr 30, 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times

Apr 30, 2025

Apr 30, 2025

New Cancer Treatment Breakthrough: Bolt Bio's Dual-Target Therapy Achieves Complete Response in Early Tests - Stock Titan

Apr 30, 2025

Apr 29, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India

Apr 29, 2025

Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025

Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus

Apr 25, 2025

Apr 25, 2025

Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India

Apr 25, 2025

Apr 25, 2025

Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq

Apr 25, 2025

Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times

Apr 25, 2025

Apr 25, 2025

Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan

Apr 25, 2025

Apr 17, 2025

Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 16, 2025

Bolt Biotherapeutics modifies quorum requirements - Investing.com

Apr 16, 2025

Apr 12, 2025

BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com

Apr 12, 2025

Apr 10, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 10, 2025

Apr 08, 2025

Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire

Apr 08, 2025

Apr 08, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 08, 2025

Apr 07, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire

Apr 07, 2025

Apr 04, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK

Apr 04, 2025

Apr 03, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

Mar 29, 2025

What is HC Wainwright’s Estimate for BOLT Q1 Earnings? - Defense World

Mar 29, 2025

Mar 28, 2025

What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings? - Defense World

Mar 28, 2025

Mar 28, 2025

Q3 Earnings Forecast for BOLT Issued By HC Wainwright - Defense World

Mar 28, 2025

Mar 26, 2025

H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock - Investing.com India

Mar 26, 2025

Mar 26, 2025

Bolt Biotherapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Mar 26, 2025

Mar 26, 2025

Bolt Biotherapeutics Inc (BOLT) Q4 2024 Earnings: EPS Misses at -$0.42, Revenue Falls Short at $0 Million - GuruFocus

Mar 26, 2025

Mar 26, 2025

Bolt Biotherapeutics’ (BOLT) Neutral Rating Reaffirmed at HC Wainwright - Defense World

Mar 26, 2025

Mar 26, 2025

Bolt Biotherapeutics (NASDAQ:BOLT) Given New $1.25 Price Target at Stifel Nicolaus - Defense World

Mar 26, 2025

Mar 25, 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times

Mar 25, 2025

Mar 25, 2025

Groundbreaking Cancer Drug Trial Results: First-Ever Dectin-2 Agonist Data Revealed at AACR 2025 - Stock Titan

Mar 25, 2025

Mar 25, 2025

Stifel cuts Bolt Biotherapeutics stock price target to $1.25 By Investing.com - Investing.com Australia

Mar 25, 2025

Mar 25, 2025

Stifel cuts Bolt Biotherapeutics stock price target to $1.25 - Investing.com

Mar 25, 2025

Mar 24, 2025

Bolt Biotherapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 24, 2025

Mar 24, 2025

Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot - The Washington Post

Mar 24, 2025

Mar 24, 2025

Bolt Biotherapeutics Updates on Clinical Trials and Financial Results, Anticipates Milestones for BDC-4182 and BDC-3042 - Nasdaq

Mar 24, 2025

Mar 24, 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 24, 2025

Mar 22, 2025

BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 22, 2025

Mar 14, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 14, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.4 - Investing.com India

Mar 14, 2025

Mar 13, 2025

Bolt Biotherapeutics (BOLT) to Release Earnings on Thursday - Defense World

Mar 13, 2025

Mar 08, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.42 By Investing.com - Investing.com Australia

Mar 08, 2025

Mar 07, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.42 - Investing.com India

Mar 07, 2025